CereHealth

Executive Summary

CereHealth is a digital health company founded in 2019 and headquartered in Austin, Texas. The company specializes in developing AI-powered diagnostic tools and integrated digital health solutions for neurological conditions, with a mission to enhance the accuracy, speed, and accessibility of neurological assessments. By leveraging artificial intelligence, CereHealth aims to address critical gaps in neurology, such as early detection of disorders like Alzheimer's, Parkinson's, and multiple sclerosis, which often suffer from delayed or subjective diagnoses. The company's platform, IllumeAI, is designed to provide clinicians with objective, data-driven insights to improve patient outcomes. Despite its promising value proposition, CereHealth remains in a relatively early stage, with limited public information on funding, revenue, or commercialization progress. The digital health diagnostics market is highly competitive but growing rapidly, driven by aging populations and increasing neurological disease prevalence. CereHealth's success will depend on its ability to achieve regulatory clearances, validate its technology through clinical studies, and secure partnerships with healthcare providers. As of early 2026, the company has not yet reported any FDA approvals or commercial product launches, indicating it is likely in the development or pilot phase. Given the current lack of transparency, the investment thesis for CereHealth carries high uncertainty but offers significant upside if the technology proves effective and gains adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for flagship AI diagnostic tool40% success
• Q3 2026Publication of peer-reviewed clinical validation study50% success
• Q1 2027Strategic partnership with a major healthcare system35% success